Cargando…

Aberrant overexpression of an epithelial marker, 14-3-3σ, in a subset of hematological malignancies

BACKGROUND: 14-3-3σ is a p53-mediated cell-cycle inhibitor in epithelial cells. The expression of 14-3-3σ is frequently altered in cancers of epithelial origin associated with altered DNA methylation. Since its involvement in a non-epithelial tumor is unknown, we examined 14-3-3σ expression in patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Motokura, Toru, Nakamura, Yukari, Sato, Hiroyuki
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2007
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2222637/
https://www.ncbi.nlm.nih.gov/pubmed/18036248
http://dx.doi.org/10.1186/1471-2407-7-217
_version_ 1782149361697816576
author Motokura, Toru
Nakamura, Yukari
Sato, Hiroyuki
author_facet Motokura, Toru
Nakamura, Yukari
Sato, Hiroyuki
author_sort Motokura, Toru
collection PubMed
description BACKGROUND: 14-3-3σ is a p53-mediated cell-cycle inhibitor in epithelial cells. The expression of 14-3-3σ is frequently altered in cancers of epithelial origin associated with altered DNA methylation. Since its involvement in a non-epithelial tumor is unknown, we examined 14-3-3σ expression in patients with haematological malignancies. METHODS: We analyzed 41 hematopoietic cell lines and 129 patients with a variety of hematological malignancies for 14-3-3σ expression with real-time RT-PCR. We also examined protein levels by Western blot analysis and DNA methylation status of the 14-3-3σ gene by methylation-specific PCR analysis of bisulfite-treated DNA. In addition, mutations of p53 gene were identified by RT-PCR-SSCP analysis and the expression levels of 14-3-3σ were compared with those of other cell-cycle inhibitor genes, CDKN2A and ARF. RESULTS: The expression levels of 14-3-3σ mRNA in almost all cell lines were low and comparable to those in normal hematopoietic cells except for 2 B-cell lines. On the contrary, 14-3-3σ mRNA was aberrantly overexpressed frequently in mature lymphoid malignancies (30 of 93, 32.3%) and rarely in acute leukemia (3 of 35, 8.6%). 14-3-3σ protein was readily detectable and roughly reflected the mRNA level. In contrast to epithelial tumors, methylation status of the 14-3-3σ gene was not associated with expression in hematological malignancies. Mutations of p53 were identified in 12 patients and associated with lower expression of 14-3-3σ. The expression levels of 14-3-3σ, CDKN2A and ARF were not correlated with but rather reciprocal to one another, suggesting that simultaneous overexpression of any two of them is incompatible with tumor growth. CONCLUSION: 14-3-3σ, an epithelial cell marker, was overexpressed significantly in a subset of mature lymphoid malignancies. This is the first report of aberrant 14-3-3σ expression in non-epithelial tumors in vivo. Since the significance of 14-3-3σ overexpression is unknown even in epithelial tumors such as pancreatic cancers, further analysis of regulation and function of the 14-3-3σ gene in non-epithelial as well as epithelial tumors is warranted.
format Text
id pubmed-2222637
institution National Center for Biotechnology Information
language English
publishDate 2007
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-22226372008-02-01 Aberrant overexpression of an epithelial marker, 14-3-3σ, in a subset of hematological malignancies Motokura, Toru Nakamura, Yukari Sato, Hiroyuki BMC Cancer Research Article BACKGROUND: 14-3-3σ is a p53-mediated cell-cycle inhibitor in epithelial cells. The expression of 14-3-3σ is frequently altered in cancers of epithelial origin associated with altered DNA methylation. Since its involvement in a non-epithelial tumor is unknown, we examined 14-3-3σ expression in patients with haematological malignancies. METHODS: We analyzed 41 hematopoietic cell lines and 129 patients with a variety of hematological malignancies for 14-3-3σ expression with real-time RT-PCR. We also examined protein levels by Western blot analysis and DNA methylation status of the 14-3-3σ gene by methylation-specific PCR analysis of bisulfite-treated DNA. In addition, mutations of p53 gene were identified by RT-PCR-SSCP analysis and the expression levels of 14-3-3σ were compared with those of other cell-cycle inhibitor genes, CDKN2A and ARF. RESULTS: The expression levels of 14-3-3σ mRNA in almost all cell lines were low and comparable to those in normal hematopoietic cells except for 2 B-cell lines. On the contrary, 14-3-3σ mRNA was aberrantly overexpressed frequently in mature lymphoid malignancies (30 of 93, 32.3%) and rarely in acute leukemia (3 of 35, 8.6%). 14-3-3σ protein was readily detectable and roughly reflected the mRNA level. In contrast to epithelial tumors, methylation status of the 14-3-3σ gene was not associated with expression in hematological malignancies. Mutations of p53 were identified in 12 patients and associated with lower expression of 14-3-3σ. The expression levels of 14-3-3σ, CDKN2A and ARF were not correlated with but rather reciprocal to one another, suggesting that simultaneous overexpression of any two of them is incompatible with tumor growth. CONCLUSION: 14-3-3σ, an epithelial cell marker, was overexpressed significantly in a subset of mature lymphoid malignancies. This is the first report of aberrant 14-3-3σ expression in non-epithelial tumors in vivo. Since the significance of 14-3-3σ overexpression is unknown even in epithelial tumors such as pancreatic cancers, further analysis of regulation and function of the 14-3-3σ gene in non-epithelial as well as epithelial tumors is warranted. BioMed Central 2007-11-25 /pmc/articles/PMC2222637/ /pubmed/18036248 http://dx.doi.org/10.1186/1471-2407-7-217 Text en Copyright © 2007 Motokura et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Motokura, Toru
Nakamura, Yukari
Sato, Hiroyuki
Aberrant overexpression of an epithelial marker, 14-3-3σ, in a subset of hematological malignancies
title Aberrant overexpression of an epithelial marker, 14-3-3σ, in a subset of hematological malignancies
title_full Aberrant overexpression of an epithelial marker, 14-3-3σ, in a subset of hematological malignancies
title_fullStr Aberrant overexpression of an epithelial marker, 14-3-3σ, in a subset of hematological malignancies
title_full_unstemmed Aberrant overexpression of an epithelial marker, 14-3-3σ, in a subset of hematological malignancies
title_short Aberrant overexpression of an epithelial marker, 14-3-3σ, in a subset of hematological malignancies
title_sort aberrant overexpression of an epithelial marker, 14-3-3σ, in a subset of hematological malignancies
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2222637/
https://www.ncbi.nlm.nih.gov/pubmed/18036248
http://dx.doi.org/10.1186/1471-2407-7-217
work_keys_str_mv AT motokuratoru aberrantoverexpressionofanepithelialmarker1433sinasubsetofhematologicalmalignancies
AT nakamurayukari aberrantoverexpressionofanepithelialmarker1433sinasubsetofhematologicalmalignancies
AT satohiroyuki aberrantoverexpressionofanepithelialmarker1433sinasubsetofhematologicalmalignancies